Top 5 Stocks to Buy Now
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free PGNY Stock Alerts

Progyny (PGNY) Competitors

Progyny logo
$26.08 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$25.29 -0.79 (-3.04%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PGNY vs. HIMS, PACS, CAI, BLLN, and SHC

Should you buy Progyny stock or one of its competitors? MarketBeat compares Progyny with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Progyny include Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), Billiontoone (BLLN), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does Progyny compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Progyny has a net margin of 5.23% compared to Hims & Hers Health's net margin of -0.56%. Progyny's return on equity of 13.34% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health-0.56% 6.10% 1.52%
Progyny 5.23%13.34%9.03%

Hims & Hers Health has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, Progyny has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Hims & Hers Health presently has a consensus price target of $29.37, indicating a potential downside of 17.14%. Progyny has a consensus price target of $29.67, indicating a potential upside of 13.75%. Given Progyny's stronger consensus rating and higher probable upside, analysts clearly believe Progyny is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
3 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.06
Progyny
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$2.35B3.49$128.37M-$0.09N/A
Progyny$1.29B1.59$58.52M$0.7733.87

In the previous week, Hims & Hers Health had 20 more articles in the media than Progyny. MarketBeat recorded 23 mentions for Hims & Hers Health and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Hims & Hers Health's score of 0.76 indicating that Progyny is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
11 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Progyny
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Progyny beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to PACS Group?

Progyny (NASDAQ:PGNY) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity.

Company Net Margins Return on Equity Return on Assets
Progyny5.23% 13.34% 9.03%
PACS Group 4.49%26.47%4.36%

94.9% of Progyny shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 70.1% of PACS Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Progyny currently has a consensus price target of $29.67, indicating a potential upside of 13.75%. PACS Group has a consensus price target of $48.00, indicating a potential upside of 30.88%. Given PACS Group's higher possible upside, analysts plainly believe PACS Group is more favorable than Progyny.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Progyny
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79
PACS Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Progyny$1.29B1.59$58.52M$0.7733.87
PACS Group$5.29B1.10$191.54M$1.5623.51

In the previous week, PACS Group had 5 more articles in the media than Progyny. MarketBeat recorded 8 mentions for PACS Group and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat PACS Group's score of -0.12 indicating that Progyny is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Progyny
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PACS Group
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Progyny beats PACS Group on 8 of the 15 factors compared between the two stocks.

How does Progyny compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Progyny has a net margin of 5.23% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Progyny's return on equity.

Company Net Margins Return on Equity Return on Assets
Caris Life Sciences3.75% 98.28% 48.87%
Progyny 5.23%13.34%9.03%

Caris Life Sciences currently has a consensus target price of $27.56, suggesting a potential upside of 49.19%. Progyny has a consensus target price of $29.67, suggesting a potential upside of 13.75%. Given Caris Life Sciences' higher possible upside, research analysts clearly believe Caris Life Sciences is more favorable than Progyny.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caris Life Sciences
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.45
Progyny
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79

Progyny has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caris Life Sciences$812.03M6.43-$68.09M-$7.61N/A
Progyny$1.29B1.59$58.52M$0.7733.87

In the previous week, Caris Life Sciences had 2 more articles in the media than Progyny. MarketBeat recorded 5 mentions for Caris Life Sciences and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Caris Life Sciences' score of 0.31 indicating that Progyny is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Caris Life Sciences
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Progyny
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

94.9% of Progyny shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Progyny beats Caris Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Progyny compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Progyny has a net margin of 5.23% compared to Billiontoone's net margin of 0.00%. Progyny's return on equity of 13.34% beat Billiontoone's return on equity.

Company Net Margins Return on Equity Return on Assets
BilliontooneN/A N/A N/A
Progyny 5.23%13.34%9.03%

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Billiontoone$305.11M15.85$7.45M$0.55191.18
Progyny$1.29B1.59$58.52M$0.7733.87

In the previous week, Billiontoone had 2 more articles in the media than Progyny. MarketBeat recorded 5 mentions for Billiontoone and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Billiontoone's score of -0.44 indicating that Progyny is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Billiontoone
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Progyny
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Billiontoone currently has a consensus price target of $125.29, suggesting a potential upside of 19.15%. Progyny has a consensus price target of $29.67, suggesting a potential upside of 13.75%. Given Billiontoone's higher possible upside, research analysts clearly believe Billiontoone is more favorable than Progyny.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Billiontoone
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Progyny
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79

94.9% of Progyny shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Progyny beats Billiontoone on 11 of the 15 factors compared between the two stocks.

How does Progyny compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

91.0% of Sotera Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sotera Health has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Progyny has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

In the previous week, Progyny had 2 more articles in the media than Sotera Health. MarketBeat recorded 3 mentions for Progyny and 1 mentions for Sotera Health. Progyny's average media sentiment score of 1.24 beat Sotera Health's score of 0.00 indicating that Progyny is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sotera Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Progyny
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sotera Health currently has a consensus price target of $20.29, suggesting a potential upside of 28.23%. Progyny has a consensus price target of $29.67, suggesting a potential upside of 13.75%. Given Sotera Health's higher probable upside, analysts plainly believe Sotera Health is more favorable than Progyny.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sotera Health
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.73
Progyny
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79

Sotera Health has a net margin of 9.91% compared to Progyny's net margin of 5.23%. Sotera Health's return on equity of 39.73% beat Progyny's return on equity.

Company Net Margins Return on Equity Return on Assets
Sotera Health9.91% 39.73% 7.05%
Progyny 5.23%13.34%9.03%

Sotera Health has higher earnings, but lower revenue than Progyny. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sotera Health$1.16B3.88$77.94M$0.4138.59
Progyny$1.29B1.59$58.52M$0.7733.87

Summary

Sotera Health and Progyny tied by winning 8 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PGNY vs. The Competition

Export
MetricProgynyMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$2.04B$8.76B$6.42B$12.59B
Dividend YieldN/A1.73%2.68%5.81%
P/E Ratio33.8724.7324.7824.44
Price / Sales1.5922.64532.71109.74
Price / Cash35.43102.9745.0755.09
Price / Book4.355.6410.806.58
Net Income$58.52M$179.69M$3.57B$337.17M
7 Day Performance-2.07%1.96%0.72%0.83%
1 Month Performance5.63%2.99%0.41%2.25%
1 Year Performance24.31%6.36%29.34%36.14%

Progyny Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PGNY
Progyny
4.0238 of 5 stars		$26.08
flat		$29.67
+13.8%		+24.3%$2.04B$1.29B33.87310
HIMS
Hims & Hers Health
3.0215 of 5 stars		$30.10
+12.2%		$28.70
-4.6%		-45.0%$6.21B$2.35BN/A2,442
PACS
PACS Group
3.7915 of 5 stars		$36.23
-0.2%		$48.00
+32.5%		+176.8%$5.74B$5.29B23.2247,455
CAI
Caris Life Sciences
4.3745 of 5 stars		$18.18
+1.2%		$27.56
+51.6%		N/A$5.08B$812.03MN/A1,846
BLLN
Billiontoone
3.2796 of 5 stars		$103.95
+2.8%		$125.29
+20.5%		N/A$4.65B$305.11M189.00620

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel